about
Onto better TRAILs for cancer treatmentDeath receptor-ligand systems in cancer, cell death, and inflammationGetting TRAIL back on track for cancer therapyTAK1 is required for survival of mouse fibroblasts treated with TRAIL, and does so by NF-kappaB dependent induction of cFLIPL.Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma.The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer.Screening of potential molecular targets for colorectal cancer therapy.Novel Structurally Related Flavones Augment Cell Death Induced by rhsTRAILHDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells.Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and BortezomibThree-dimensional microscopy characterization of death receptor 5 expression by over-activated human primary CD4+ T cells and apoptosis.Selective TRAIL-triggered apoptosis due to overexpression of TRAIL death receptor 5 (DR5) in P-glycoprotein-bearing multidrug resistant CEM/VBL1000 human leukemia cellsThe inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells.Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins.TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.Synergistic Effect of Subtoxic-dose Cisplatin and TRAIL to Mediate Apoptosis by Down-regulating Decoy Receptor 2 and Up-regulating Caspase-8, Caspase-9 and Bax Expression on NCI-H460 and A549 Cells.Regulating TRAIL receptor-induced cell death at the membrane : a deadly discussionLyapunov exponents and phase diagrams reveal multi-factorial control over TRAIL-induced apoptosis.The novel Akt inhibitor API-1 induces c-FLIP degradation and synergizes with TRAIL to augment apoptosis independent of Akt inhibition.Cyproterone acetate enhances TRAIL-induced androgen-independent prostate cancer cell apoptosis via up-regulation of death receptor 5A promising "TRAIL" of tanshinones for cancer therapy.Glycogen synthase kinase-3β regulates tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis via the NF-κB pathway in hepatocellular carcinoma.Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors.Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activityTRAIL conjugated to nanoparticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and in vivoThe oncogene metadherin modulates the apoptotic pathway based on the tumor necrosis factor superfamily member TRAIL (Tumor Necrosis Factor-related Apoptosis-inducing Ligand) in breast cancer.Immunomodulatory effects of interferons in malignancies.Therapeutic development in targeting protein-protein interactions with synthetic topological mimetics.Altered expression of mir-222 and mir-25 influences diverse gene expression changes in transformed normal and anaplastic thyroid cells, and impacts on MEK and TRAIL protein expression.Therapeutic applications of TRAIL receptor agonists in cancer and beyond.Membrane expression of TRAIL receptors DR4, DR5, DcR1 and DcR2 in the normal endometrium, atypical endometrial hyperplasia and endometrioid adenocarcinoma: a tissue microarray study.TRAIL-deficient mice exhibit delayed regression of retinal neovascularization.Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1.The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2.Towards novel paradigms for cancer therapy.Naturally occurring, tumor-specific, therapeutic proteins.TRAIL-mediated signaling in prostate, bladder and renal cancer.Transcriptional regulation of tumour necrosis factor-related apoptosis-inducing ligand.Evaluation of the safety and efficacy of TRAIL and taurolidine use on human fibrosarcoma xenografts in vivo.An Approach to Breast Cancer Immunotherapy: The Apoptotic Activity of Recombinant Anti-Interleukin-6 Monoclonal Antibodies in Intact Tumour Microenvironment of Breast Carcinoma.
P2860
Q26768160-B917D7AA-EB3C-4900-8DA2-8AD54CAAA9B3Q26865568-720A9AF5-9663-48BC-BF4F-BDEE7E33F907Q27027460-2E8CB35B-EE5A-4D89-AA35-60F612125783Q33523025-4577513E-771B-43D6-B765-E1605631390AQ33544118-A0C705FC-F0D4-456D-8B91-932FA48C7B93Q33650479-15043D53-6C3B-4EEF-8978-6014AFA1BC7DQ33735051-3178E865-3761-4270-ADC6-581ED4F447EDQ33838733-D9BE5E6E-04D2-4174-9742-44A25F3B72ECQ33842416-7551DE36-3577-48D9-B090-DEB4893B0616Q33906039-9ABAD202-DA4A-4354-80A8-3D84BFC27557Q34193462-F6380646-2929-433A-AE4B-DBCDD3D39981Q34193833-436BCF8F-F785-495D-946C-215CE62E632EQ34428852-6F7314AD-E43E-46EF-A136-B6DF3BD9600BQ34546374-2C4ED35F-1993-48DD-A10C-CBD143D17F0CQ34557885-BA582960-4A77-44B5-B6AD-675ACF0F6F1AQ34798109-61F1D3A5-AA91-4B01-BA74-FEF81C51C298Q35480734-96E26ECD-9E43-434A-94F8-FB074201611EQ35682077-3677D870-2786-4725-BE1F-DE1D19F0880BQ35884130-53AFC6E1-CD25-4310-A485-B1CE91523E96Q36300065-DF277A3E-ED4B-448E-8CB2-DDC8A437B215Q36332681-A2894674-79DC-4922-A35F-1654D63630C0Q36335972-98A4C656-4CCB-4391-BAF5-EFC60E0B65F2Q36395984-06BF898A-3FF1-4810-817B-4D69A8322B53Q36499644-A75702D2-A72F-45FE-98C5-BE8310449D2DQ36500367-20268151-FC66-4B2F-BF8A-1479B43B7548Q36725089-8A81FAD5-1B15-418F-8C31-958D0E4A652FQ36825411-F5CD7356-C3D6-4EF8-A569-5030105E1F15Q36865196-93CB71FC-20D2-4DAE-BE80-C318EAD691F7Q37071712-E74A2226-E5C3-4285-AD12-77DB36D51A6CQ37114025-2932DDD1-14D5-401A-ACCC-68EA0B63521FQ37185605-28ED0A22-3C8D-4530-A11F-ABA1E7554076Q37462599-B5183E56-3012-4E2D-A192-EC4E7A1DE327Q37578817-0024CA14-D4CB-46AF-A2C3-75345B912E23Q37651394-AB7C0060-5159-4951-A38F-8FE6B3268F9AQ37799251-81F923D3-BA90-49C2-982E-43ACCC527C2AQ37869260-945E3477-67EB-437B-B505-2C1E9209DC3AQ37889112-6D7F50CE-3F69-41A0-8073-153BC9C4B04DQ38074861-584013F8-6487-48FE-9203-555EBACE68E6Q38721053-88228D4C-8B80-4E26-9A83-F65E89590D53Q38786771-9DC459E0-F4F9-4286-B472-0550A6BEF781
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Is TRAIL the holy grail of cancer therapy?
@en
Is TRAIL the holy grail of cancer therapy?
@nl
type
label
Is TRAIL the holy grail of cancer therapy?
@en
Is TRAIL the holy grail of cancer therapy?
@nl
prefLabel
Is TRAIL the holy grail of cancer therapy?
@en
Is TRAIL the holy grail of cancer therapy?
@nl
P2093
P2860
P1433
P1476
Is TRAIL the holy grail of cancer therapy?
@en
P2093
Henning Walczak
Silvia Prieske
Thomas Newsom-Davis
P2860
P2888
P304
P356
10.1007/S10495-009-0321-2
P577
2009-04-01T00:00:00Z